Glaucoma Market Report 2026

The glaucoma market size has grown strongly in recent years. It will grow from $8.2 billion in 2025 to $8.65 billion in 2026 at a compound annual growth rate (CAGR) of 5.5%. The growth in the historic period can be attributed to aging population, increased eye disease prevalence, advancement in ophthalmic diagnostics, early drug therapy adoption, growth of eye clinics.

The glaucoma market size is expected to see strong growth in the next few years. It will grow to $10.62 billion in 2030 at a compound annual growth rate (CAGR) of 5.3%. The growth in the forecast period can be attributed to technological advancements in imaging, expansion of surgical innovations, digital eye health monitoring, early detection initiatives, rising ophthalmology investments. Major trends in the forecast period include rising adoption of early diagnostic screening, increased use of combination drug therapies, growth of minimally invasive glaucoma surgery, expansion of home-based eye monitoring, improved patient awareness programs.

The rising prevalence of chronic eye conditions is expected to drive the growth of the glaucoma market in the coming years. Chronic eye conditions are long-term disorders affecting the eyes, often causing persistent vision impairment or discomfort and requiring ongoing management or treatment. The increase in chronic eye conditions is attributed to aging populations, prolonged screen time, lifestyle factors, and a higher prevalence of diseases such as diabetes and hypertension. Glaucoma treatment is essential for these conditions to lower intraocular pressure, prevent further optic nerve damage, and preserve vision, as untreated glaucoma can result in irreversible blindness. For instance, in December 2024, the National Health Service (NHS), a UK-based publicly funded healthcare system, reported that over 2 million people in the UK were living with sight loss in 2024, with projections indicating a 27% increase to approximately 2.8 million by 2035. Therefore, the rising prevalence of chronic eye conditions is driving the glaucoma market.

Major companies in the glaucoma market are focusing on innovative therapies, such as Rho-kinase (ROCK) inhibitors, which provide a dual mechanism of action by reducing intraocular pressure through both enhanced aqueous humor outflow and relaxation of trabecular meshwork cells, making them effective in glaucoma treatment. Rho-kinase (ROCK) inhibitors target and block the activity of Rho-kinase enzymes, which regulate cell contraction and help lower intraocular pressure. For instance, in July 2023, Santen Pharmaceutical Co. Ltd., a Japan-based eye care company, launched Roclanda in the UK. Roclanda is a fixed-dose combination (FDC) of latanoprost and netarsudil, a novel Rho-kinase (ROCK) inhibitor, that effectively reduces intraocular pressure by targeting trabecular meshwork dysfunction. It is indicated for adults with primary open-angle glaucoma or ocular hypertension who have not achieved adequate IOP reduction with monotherapy using a prostaglandin or netarsudil. The launch of Roclanda in Europe represents the first new class of glaucoma medication in 25 years, providing a breakthrough in treatment. By combining netarsudil and latanoprost, Roclanda works synergistically to enhance outflow through both trabecular (conventional) and uveoscleral (unconventional) pathways, offering a comprehensive approach to managing elevated intraocular pressure.

In December 2024, Bausch + Lomb Corp., a Canada-based healthcare company, acquired Elios Vision Inc. for an undisclosed amount. This acquisition enables the development of more effective glaucoma treatments without the need for implants, enhancing the company’s ability to provide comprehensive solutions. It also highlights Bausch + Lomb’s commitment to investing in technologies that help eye care professionals better address patients’ evolving needs. Elios Vision Inc. is a US-based developer specializing in minimally invasive glaucoma surgery (MIGS) procedures.

Major companies operating in the glaucoma market are Roche Holding AG, Merck & Co. Inc., AbbVie Inc., Novartis AG, Teva Pharmaceuticals Industries Ltd., Otsuka Pharmaceutical Co. Ltd., Sun Pharmaceutical Industries Ltd., Cipla Limited, Bausch & Lomb Corp., Carl Zeiss Meditec, Santen Pharmaceuticals Co. Ltd., Topcon Corporation, Thea Laboratoires, Corza Ophthalmology, Lumenis Ltd., Alcon Inc., Glaukos Corporation, Iridex Corporation, Nova Eye Medical Ltd., Nidek Co. Ltd., Haag-Streit AG.

North America was the largest region in the glaucoma market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the glaucoma market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the glaucoma market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs are impacting the glaucoma market by increasing costs of imported ophthalmic drugs, diagnostic devices, and surgical equipment. Hospitals and ophthalmic clinics are most affected due to reliance on imported technologies. These tariffs increase treatment costs by raising expenses for long-term drug therapy, diagnostic monitoring, and surgical intervention. However, they support local ophthalmic device manufacturing, strengthening regional production of diagnostic and surgical equipment.

The glaucoma market research report is one of a series of new reports that provides glaucoma market statistics, including glaucoma industry global market size, regional shares, competitors with a glaucoma market share, detailed glaucoma market segments, market trends and opportunities, and any further data you may need to thrive in the glaucoma industry. This glaucoma market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Glaucoma is a group of eye disorders that cause damage to the optic nerve, usually due to increased intraocular pressure (IOP). This damage can result in progressive and irreversible vision loss if left untreated, making glaucoma a leading cause of blindness worldwide. Early detection through regular eye examinations is essential to prevent vision loss.

The main types of glaucoma include open-angle glaucoma, angle-closure glaucoma, and others. Open-angle glaucoma is a form of glaucoma in which the eye's drainage angle remains open, but the trabecular meshwork becomes gradually blocked, causing increased intraocular pressure (IOP). Diagnosis can be made using tonometry, ophthalmoscopy, perimetry, and gonioscopy. Treatment involves various drug classes, including beta-blockers, prostaglandins, alpha-adrenergic agonists, carbonic anhydrase inhibitors, combination drugs, and others. These medications are administered orally, by injection, intravitreally, and via other routes, and are used by hospitals, ophthalmic clinics, and ambulatory surgical centers.

The glaucoma market consists of revenues earned by entities by providing services such as surgical services, telemedicine consultations, treatment monitoring and custom surgical planning. The market value includes the value of related goods sold by the service provider or included within the service offering. The glaucoma market also includes sales of laser treatment devices, glaucoma drainage implants, visual field analyzers and surgical tools. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.